Expert Opinion on Drug Safety

Article	Citations
Novel insights into post-marketing AEs associated with bempedoic acid: a comprehensive analysis utilizing the FAERS database	86
Drug-induced hepatitis B virus reactivation: insights from FAERS database analysis	69
Adverse event profiles of drug-induced decreased libido: an assessment of the US food and drug administration Adverse Event Reporting System	68
Resistance to hedgehog inhibitors in basal cell carcinoma: strategies to adopt	59
Assessment of adverse events of the novel antiepileptic drug lamotrigine: a real-world pharmacovigilance study based on FAERS	53
Adverse events in patients with cardiovascular disease taking proton pump inhibitors	50
The role of artificial intelligence in pharmacovigilance for rare diseases	44
Exploration and evaluation of adverse event signals of droxidopa based on the FAERS database	42
Safety profile of isocitrate dehydrogenase inhibitors in cancer therapy: a pharmacovigilance study of the FDA Adverse Event Reporting System	39
Exploration of cardiac adverse events associated with relugolix and degarelix: a multi-center pharmacovigilance study based on the FAERS database	38
An updated safety review of Hidradenitis Suppurativa treatment options	36
Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile	36
The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism	34
Infectious events in patients with alopecia areata treated with JAK inhibitors: low burden and minimal impact on persistence in treatment	33
Thromboembolic events in younger women exposed to Pfizer-BioNTech or Moderna COVID-19 vaccines	33
Comparison of adverse events of poly adenosine diphosphate ribose polymerase inhibitors in patients with ovarian cancer using the United States Food and Drug Administration Adverse Event Reporting Sys	32
An update on the cognitive safety of antimuscarinics in the treatment of overactive bladder	29
Mechanism and clinical utility of abatacept in the treatment of rheumatoid arthritis	29
The safety of phthalate-containing medications used during pregnancy	27
Assessment of adverse events related to anti-interleukin-6 receptor monoclonal antibodies using the FDA adverse event reporting system: a real-world pharmacovigilance study	25
Long-term safety of ketamine and esketamine in treatment of depression	24
Safety assessment of brexanolone in the FAERS database: real adverse event analysis and discussion of side effects	24
Gastrointestinal and cardiovascular adverse events associated with NSAIDs	23
A real-world pharmacovigilance study of QT interval prolongation and Torsades de Pointes associated with CDK4/6 inhibitors in breast cancer patients: findings from the FDA adverse event reporting syst	23
Newly identified adverse events of enzalutamide using the food and drug administration adverse event reporting system	22

The safety profile of azithromycin in pediatrics: a pharmacovigilance disproportionality analysis	22
Safety considerations with the use of platelet inhibitors for elderly patients with non-ST- elevation acute coronary syndrome	21
Diarrhea-predominant irritable bowel syndrome treatment options eluxadoline, rifaximin, and alosetron: analysis of the FDA adverse event reporting system (FAERS) database	21
Safety concerns associated with BACE1 inhibitors – past, present, and future	21
Pharmacovigilance approaches to study rare and very rare side-effects: the example of clozapine-related DiHS/DRESS syndrome	20
Risk of acute kidney injury in patients receiving vancomycin and concomitant piperacillin-tazobactam or carbapenem: a multicenter, retrospective cohort study	19
The effectiveness and safety of aripiprazole, bromocriptine, and cabergoline in the treatment of hyperprolactinemia: a systematic review and network meta-analysis	19
The Impact of Medication Regimen Complexity Score on Multi-Organ Dysfunction and Clinical Outcomes in Critically Ill Patients: A Cohort Study	19
Proton pump inhibitors and increased reporting odds of renal neoplasms: FAERS-based adverse event data mining and analysis	18
Unveiling the hidden ocular risks of isotretinoin: a comprehensive FAERS-Based analysis	18
Safety evaluation of the DTaP5-IPV-Hib-HepB vaccine: a review	18
Safety and efficacy of anti-SARS-CoV-2 monoclonal antibodies in pregnancy	18
Correction	17
Does the use of generative AI chatbots by patients introduce risk of adverse drug events?	17
Long-term safety and effectiveness of vonoprazan for prevention of gastric and duodenal ulcer recurrence in patients on nonsteroidal anti-inflammatory drugs in Japan: a 12-month post-marketing surveil	17
A review of hydroxyurea-related cutaneous adverse events	17
Gastrointestinal adverse events associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the EudraVigilance and VigiAccess databases	17
Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance study	16
Post-marketing safety concerns with palbociclib: a disproportionality analysis of the FDA adverse event reporting system	16
SSRI withdrawal syndrome in children and adolescents: a narrative literature review	16
Disease-specific ADRs of TNF-α inhibitors as reported by patients with inflammatory rheumatic diseases: a registry-based prospective multicenter cohort study	16
First-time adverse drug reactions, survival analysis, and the share of adverse drug reactions in treatment discontinuation in real-world rheumatoid arthritis patients: a comparison of first-time treat	16
Safety of current antiviral drugs for chronic hepatitis B	16
Corticosteroids for the treatment of Duchenne muscular dystrophy: a safety review	15
Comparative analysis of CDKI-related adverse events in older patients: a real-world data from the FDA adverse event reporting system database	15
Sodium-glucose cotransporter-2 inhibitors and cardiovascular safety profile: a pharmacovigilance analysis of the US food and drug administration adverse event reporting system	15
Update of safety profile of levonorgestrel: a disproportionality analysis based on FAERS from 2004 to 2023	14
Hallucinations and delusions associated with Parkinson’s disease psychosis: safety of current treatments and future directions	14
The safety of available treatment options for short bowel syndrome and unmet needs	14
Tirzepatide and glucagon-like peptide-1 receptor agonists: safety always comes first!	14
Severe and persistent mental illness (SPMI) in pregnancy and breastfeeding: focus on second-generation long acting injectable antipsychotics	14
Data mining for signal detection of adverse events for taxanes based on the food and drug administration adverse drug events reporting system database	14
Post-marketing safety evaluation of zanubrutinib: a real-world pharmacovigilance analysis based on the FAERS database	14
Safety of intranasal corticosteroids for allergic rhinitis in children	14
A real-world disproportionality analysis of baloxavir marboxil: post-marketing pharmacovigilance data	14
Anticoagulant-associated calciphylaxis: analysis of USFDA adverse event report system and clinical feature analysis of reported cases	13
Safety considerations for prescribing SSRI antidepressants to patients at increased cardiovascular risk	13
Disproportionality analysis of the safety profile of rufinamide in the real world: an evaluation of the FDA Adverse Event Reporting System database	13
Cardiovascular adverse events in patients with HER2-positive breast cancer treated with trastuzumab-drug conjugates : a Bayesian disproportional real world study for signal detection leveraging the FD	13
Drug-induced myocarditis: a real-world pharmacovigilance study using the FDA adverse event reporting system database	12
Assessment of adverse events of tasimelteon: a real-world pharmacovigilance study based on FAERS	12
Data pharmacovigilance analysis of medroxyprogesterone-related adverse events in the FDA adverse event reporting system	12
A safety evaluation of sucroferric oxyhydroxide for the treatment of hyperphosphatemia	11
Efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors as second-line treatment in postmenopausal patients with hormone receptor-positive, HER-2-negative metastatic breast cancer: a network meta-a	11
Development and validation of a nomogram to predict the risk of potentially inappropriate medication use in older lung cancer outpatients with multimorbidity	11
Long-term safety profile and secondary effectiveness of canakinumab in pediatric rheumatic diseases: a single-center experience	11
Adverse events associated with acute pancreatitis caused by immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database	11
Drug safety evaluation of ixekizumab for psoriasis: a review of the current knowledge	11
Treatment free remission (TFR) after second-generation tyrosine kinase inhibitors (2G-TKIs) treatment in chronic myeloid leukemia (CML): from feasibility to safety	11
Current safety concerns about the use of antiseizure medications in pregnancy	11

Influence factors of metronidazole-related CNS disorders: an analysis of the Japan adverse drug event report and FDA adverse event reporting system	11
Exploration of the clinical characteristics and potential mechanisms of liver injury induced by proton pump inhibitors	11
Safety considerations for drugs newly approved for treating acute myeloid leukemia	11
The safety of current treatment options for advanced esophageal cancer after first-line chemotherapy	10
The use of hydroxyurea in the real life of MIOT network: an observational study	10
A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system	10
Differences in safety profiles of anti-herpesvirus medications: a real-world pharmacovigilance study based on the FAERS database	10
Drug-induced erectile dysfunction: a real-world pharmacovigilance study using the FDA adverse event reporting system database	10
How do safety warnings on medicines affect prescribing?	10
Comparative effectiveness and safety of drug therapy for chronic urticaria: a network meta-analysis and risk-benefit assessment	10
Antibody-drug conjugates-related interstitial lung diseases: data mining of the FAERS database	10
Vancomycin and linezolid: severe cutaneous adverse reactions to drugs	10
Association between dual orexin receptor antagonists (DORAs) and suicidality: reports to the United States Food and Drug Administration Adverse Event Reporting System (FAERS)	10
Long-term safety of lanthanum carbonate in the real word: a 19-year disproportionality analysis from the FDA Adverse Event Reporting System	10
What about regular hematological monitoring during clozapine treatment? A compliance analysis using the French health insurance database	10
Adverse events associated with inclisiran: a real-world disproportionality analysis based on the FAERS database	9
Updated insights on levetiracetam-associated severe cutaneous adverse reactions: a real-world pharmacovigilance analysis	9
Adverse event signal analysis of type Ib MET tyrosine kinase inhibitors based on food and drug administration adverse event reporting system	9
Reporting, handling, and subjective importance of adverse drug reactions among general practitioners: an exploratory cross-sectional survey	9
Safety of marketed biosimilar monoclonal antibody cancer treatments in the US: a disproportionality analysis using the food and drug administration adverse event reporting system (FAERS) database	9
Drug-induced hyperacusis: a disproportionality analysis of the FAERS database	9
Adverse event profile of ocular injury associated with JAK inhibitors in patients with rheumatoid arthritis: a disproportionality analysis	9
Hemorrhage profile associated with immune checkpoint inhibitors: a systematic review and a real-world study based on the FAERS database	9
Adverse events of direct factor Xa inhibitors: a disproportionality analysis of the FAERS database	9
Adverse events associated with aromatase inhibitors: an analysis of real-world datasets and drug-gene interaction network	9
Skin cancer associated with calcineurin inhibitors treatment: analysis of FAERS database	8
Congenital anomalies associated with the use of cardiovascular drugs during pregnancy: a large-scale data analysis from the FAERS database	8
Biosimilars and immunogenicity: a matter of concern?	8
A review on side effect management of second-generation antipsychotics to treat schizophrenia: a drug safety perspective	8
Safety profile of D-penicillamine: a comprehensive pharmacovigilance analysis by FDA adverse event reporting system	8
Treating psychosis in people with Parkinson’s disease	8
Safety considerations with new antibacterial approaches for chronic bacterial prostatitis	8
Potential drugs for reducing the occurrence of immune checkpoint inhibitor-induced interstitial lung disease: an exploratory study using the JADER and FAERS databases	8
Will the future of pharmacovigilance be more automated?	8
Detection of risk signals for ustekinumab in the real world using the FDA Adverse Event Reporting System (FAERS)	8
Patients’ perspectives on a drug safety monitoring system for immune-mediated inflammatory diseases based on patient-reported outcomes	8
Impact of preoperative pharmaceutical care consultation on medication errors in surgical patients: a comprehensive analysis	8
A review of the evidence on the risk of congenital malformations and neurodevelopmental disorders in association with antiseizure medications during pregnancy	8
Comparing musculoskeletal and connective tissue disorder risks of teriparatide and abaloparatide in osteoporosis: an analysis based on FDA adverse event reporting system (FAERS)	8
Ocular toxicities associated with antibody drug conjugates and immunotherapy in oncology: clinical presentation, pathogenesis, and management strategies	8
Safety evaluation of ILaris: a real-world analysis of adverse events based on the FAERS database	8
A real‑world pharmacovigilance study of FDA adverse event reporting system events for daratumumab	8
Generic pharmaceuticals, regulatory aspects, bioequivalence investigation, and perception	8
Hepatobiliary disorders and Direct-Acting Antiviral (DAA) therapies: real-world evidence and insights from the EudraVigilance database	7
Risk factors analysis and construction of predictive models for acute kidney injury in overweight patients receiving vancomycin treatment	7
Safety profiles of tetracycline-class drugs: a pharmacovigilance analysis of the FAERS database	7
Ocular adverse events of cenegermin used in neurotrophic keratopathy: an analysis of the FDA adverse event reporting system database	7
Comparison of four criteria for potentially inappropriate medications in older patients with newly diagnosed non-small cell lung cancer	7
Opioid-related adverse drug events in surgical patients: risk factors and association with clinical outcomes	7
An update on the safety of ixazomib for the treatment of multiple myeloma	7
Liver toxicity in oncology trials and beyond: a simplified concept for management of hepatocellular drug-induced liver injury in patients with abnormal baseline liver tests	7
Real-world safety evaluation of brivaracetam: insights from the US FDA Adverse Event Reporting System	7
Cognitive dysfunction following finasteride use: a disproportionality analysis of the global pharmacovigilance database	7
Completeness of pharmaceutical industry insulin adverse event reports from Africa and the Middle East	7
Investigating bleeding adverse events associated with BTK inhibitors in the food and drug administration adverse event reporting system (FAERS)	7
Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges	7
Safety evaluation of secukinumab in pediatric patients with plaque psoriasis	7
Safety of medications for hereditary angioedema during pregnancy and lactation	7
Cardiovascular toxicities of selective ret-specific tyrosine kinase inhibitors: a pharmacovigilance study based on the United States Food and Drug Administration Adverse Event Reporting System databas	7
Drug-induced dementia: a pharmacovigilance analysis of the FAERS database	7
Reporting of tumor lysis syndrome with targeted therapy for hepatic cancer in the FDA adverse events reporting system	7
Effects of adding adjuvants to propofol on the post-anesthesia cognitive function in patients undergoing gastroscopy/colonoscopy: a systematic review and meta-analysis	7
The role of co-morbidities in the development of an AEFI after COVID-19 vaccination in a large prospective cohort with patient-reported outcomes in the Netherlands	7
Nobel Prize for immune checkpoint inhibitors, understanding the immunological switching between immunosuppression and autoimmunity	7
Contributory factors and patient harm including deaths associated direct acting oral anticoagulants (DOACs) medication incidents: evaluation of real world data reported to the National Reporting and L	7
The efficacy and safety of Capivasertib (AZD5363) in the treatment of patients with solid tumor: a systematic review and meta-analysis of randomized clinical trials	7
Postmarketing safety of [ 177 Lu]Lu-PSMA-617 radioligand therapy for prostate cancer: a disproportionality analysis of the FDA adverse event reporting system	6
Drug-induced Stevens-Johnson syndrome: a disproportionality analysis from the pharmacovigilance database of the World Health Organization	6
Investigating the risk of deep vein thrombosis with JAK inhibitors: a disproportionality analysis using FDA Adverse Event Reporting System Database (FAERS)	6
The impact of the COVID-19 pandemic on adverse events associated with ACEIs and ARBs: a real-world analysis using the FDA adverse event reporting system	6
Study on analgesic-induced endocrine gland damage and its potential mechanisms	6
Comparative evaluation of adverse drug reactions for tenofovir alafenamide and tenofovir disoproxil fumarate using the FAERS Database: a disproportionality analysis	6
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients	6
Drug-induced nephrolithiasis: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System	6
Meeting report: an exploration into the scientific and regulatory aspects of pharmaceutical drug quality in the United States	6
Safety of lenalidomide for maintenance treatment of patients with multiple myeloma following autologous stem cell transplantation	6
Correction	6
Adverse events associated with inclisiran: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS)	6
A new paradigm in adverse drug reaction reporting: consolidating the evidence for an intervention to improve reporting	6
Safety evaluation of oliceridine for the management of postoperative moderate-to-severe acute pain	6

Antifungal agents and the kidney: pharmacokinetics, clinical nephrotoxicity, and interactions	6
Immune checkpoint inhibitor related myositis: an observational, retrospective, pharmacovigilance study	6
Can the revival of serotonergic psychedelic drugs as treatments for mental disorders help to characterize their risks and benefits?	6
Signal mining and gender differences analysis of adverse events in NMIBC treatment with gemcitabine and BCG bladder instillation based on the FAERS database	6
Oral isotretinoin for acne: a complete overview	6
Clozapine may consistently protect from suicidal behaviors while other antipsychotics may lack a specific protective effect: a comprehensive VigiBase study interpreted in the context of the prior lite	6
Seizures associated with antibiotics: a real-world disproportionality analysis of FAERS database	6
Dupilumab in real-life settings: a review of adverse events and their pathogenesis	6
Antimicrobial resistance and the post antibiotic era: better late than never effort	6
Management of refractory checkpoint inhibitor-induced colitis	5
Cardiovascular adverse events associated with EGFR and HER2 dual TKIs: a pharmacovigilance study based on the FAERS database	5
A real-world pharmacovigilance study of blinatumomab based on the FDA adverse event reporting system	5
The safety and efficacy of sugammadex for reversing neuromuscular blockade in younger children and infants	5
Assessment of safety profile of ivabradine in real-world scenario using FDA adverse event reporting system database	5
Ten years-experience of sunitinib in the treatment of advanced pan-NETs: an update on safety profile	5
The therapeutic potential of psilocybin: a systematic review	5
Barriers and facilitators for systematically registering adverse drug reactions in electronic health records: a qualitative study with Dutch healthcare professionals	5
Breast cancer treatment-related cardiovascular disturbances: advocacy for a watchful attitude in this never-ending story	5
Post-marketing safety of panitumumab: a real-world pharmacovigilance study	5
Pre- and post-operative safety considerations for patients undergoing percutaneous nephrolithotomy	5
Safety assessment of tafamidis: a real-world adverse event analysis from the FAERS database	5
Reviewing the evidence surrounding preservative-free tafluprost/timolol fixed-dose combination therapy in open-angle glaucoma and ocular hypertension management: a focus on efficacy, safety, and toler	5
Post-marketing safety surveillance of Amivantamab: a real world study based on the FDA adverse event reporting system	5
A systematic review on pediatric medication errors by parents or caregivers at home	5
Safety of ramucirumab treatment in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein	5
Intraocular inflammation as a major adverse event of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration: from clinical trials to real-world practice	5
A narrative review of the comparative safety of disease-modifying anti-rheumatic drugs used for the treatment of rheumatoid arthritis	5
A comparative analysis of the safety profiles between inclisiran and other PCSK9 inhibitors from real-world evidence – what have we learned recently?	5
Safety review of anti-VEGF therapy in patients with myopic choroidal neovascularization	5
Analyzing the patterns of adverse drug reactions due to anti-infectives from large-scale nationwide database in Thailand	5
Comment about the safety of intravenous voriconazole formulated with sulfobutylether beta-cyclodextrin	5
Concomitant use of sodium-glucose co-transporter 2 inhibitors and metformin and the risk of osteomyelitis reporting: a disproportionality analysis based on FAERS database	5
The effect of patient sex on the efficacy and safety of anticancer immunotherapy	5
COMfort Eye Trial (COMET) results - a non-inferiority, randomized, investigator-masked, two-parallel group, phase III clinical trial, to evaluate the efficacy and safety of a preservative free formula	5
Safety and tolerability of linagliptin in Asians with type 2 diabetes: a pooled analysis of 4457 patients from 21 randomized, double-blind, placebo-controlled clinical trials	5
Central serous chorioretinopathy secondary to drugs: a real-world pharmacovigilance study of the FDA adverse event reporting system (FAERS)	4
Identification of novel signal of Raynaud’s phenomenon with Calcitonin Gene-Related Peptide(CGRP) antagonists using data mining algorithms and network pharmacological approaches	4
Current treatment options for secondary hyperparathyroidism in patients with stage 3 to 4 chronic kidney disease and vitamin D deficiency	4
No association between recent antibiotic use and risk of rheumatoid arthritis: results from two prospective cohort studies	4
An umbrella review of systematic reviews on contributory factors to medication errors in health-care settings	4
PD-1/PD-L1 inhibitors-associated cardiac adverse events: a retrospective and real-world study based on the FDA Adverse Event Reporting System (FAERS)	4
Dalbavancin in the treatment of acute bacterial skin and skin structure and other infections: a safety evaluation	4
Potential side effects of currently available pharmacotherapies in male lower urinary tract symptoms suggestive of benign prostatic hyperplasia	4
Incidence and risk of treatment-related fatal adverse events in cancer patients treated with antibody conjugated drugs: a systematic review and meta-analysis of randomized controlled trials	4
Compared of efficacy and safety of high-dose donepezil vs standard-dose donepezil among elderly patients with Alzheimer’s disease: a systematic review and meta-analysis	4
The safety of available pharmacotherapy for stroke prevention in atrial fibrillation	4
Serotonin 5-HT 2B receptor agonism and valvular heart disease: implications for the development of psilocybin and related agents	4
Comparative safety review of antithrombotic treatment options for patients with atrial fibrillation undergoing percutaneous coronary intervention	4
Post-marketing safety monitoring of tirzepatide: a pharmacovigilance study based on the FAERS database	4
Evaluation of the safety and efficacy of biosimilar recombinant growth hormone in children with growth hormone deficiency: non-inferiority, randomized, parallel, multicentric and Phase III trial	4
Examining the safety of belimumab, especially in children: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database	4
Major adverse events associated with lipid reduction in inclisiran: a pharmacovigilance research of the FAERS database	4
Correction	4
Adverse event profile of setmelanotide in obesity: an integrated assessment and systematic review using disproportionality analysis, case reports and meta-analysis	4
A real-world pharmacovigilance case/non-case study of FDA adverse event reporting system events for mannitol	4
Appropriateness of psychopharmacological therapies to psychiatric diagnoses in persons with autism spectrum disorder with or without intellectual disabilities: a cross-sectional analytic study	4
Pharmacovigilance insights into drug-induced cystitis: analysis of FDA data from 2004 to 2024	4
Risk of serious skin and subcutaneous tissue disorders for nimesulide among the pediatric population: a jeopardy identified through the analysis of global individual case safety reports	4
Risk factors, prevention and treatment of weight gain associated with the use of antidepressants and antipsychotics: a state-of-the-art clinical review	4
Infectious complications associated with immune and targeted anti-cancer therapies: a retrospective study of the FDA adverse events reporting system (FAERS)	4
Online information discrepancies regarding safety of medicine use during pregnancy and lactation: an IMI ConcePTION study	4
Incidence, clinical characteristics and related drugs analyzing of drug-induced movement disorders in 102914 inpatients: a retrospective real-world study	4
Comparison of safety of acetaminophen and ibuprofen in minors: based on the FAERS database	4
Cyclin-dependent kinase 4/6 inhibitor-associated pulmonary toxicity: a disproportionality analysis from 2015 to 2023 based on the FAERS database	4
Assessment of Riociguat-related adverse events: a disproportionality analysis utilizing the FDA adverse event reporting system database	4
New exploration of signal detection of Regional Risks from the perspective of data mining: a pharmacovigilance analysis based on spontaneous reporting data in Zhenjiang, China	4
Hematopoietic adverse events associated with PARP inhibitors: A FAERS database study	4
Improving the risk-to-benefit ratio of inhaled corticosteroids through delivery and dose: current progress and future directions	4
Pulmonary adverse events associated with amiodarone: a real-world pharmacovigilance study based on the FDA adverse event reporting system	4
Quality of life in ovarian cancer patients treated with bevacizumab: a meta-analysis	4
Safety of PARP inhibitors as maintenance therapy in ovarian cancer	4
Systemic quinolones and risk of retinal detachment I: analysis of data from the US FDA adverse event reporting system	4
Characteristics of adverse drug reactions induced by flutamide and bicalutamide: a real-world pharmacovigilance study using FAERS	4
Safety analysis of fluoroquinolone drugs in elderly patients over 65 based on FAERS	4
Injection site reactions resulting from the use of biological therapy in the treatment of moderate-to-severe plaque psoriasis	4
Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis	4
A retrospective study to evaluate Hy’s Law, DrILTox ALF score, Robles-Diaz model, and a new logistic regression model for predicting acute liver failure in Chinese patients with drug-induced liver inj	4
Approved treatments for neovascular age-related macular degeneration: current safety and future directions	4
Is the psychedelic experience an essential aspect of the therapeutic effect of serotonergic psychedelics? Conceptual, discovery, development and implementation implications for psilocybin and related	4
Post-marketing safety assessment of constipation drugs: a real-world pharmacovigilance study based on FAERS database	4
Anaphylactic risk associated with iodinated and gadolinium-based contrast media	4
Signal of dementia with proton pump inhibitor after minimizing competition bias: an updated disproportionality analysis	3
Pharmacovigilance analysis of cardiac risks associated with Bruton tyrosine kinase inhibitors	3
Nail lichen planus treatment safety	3
Analysis of clinical characteristics of terbinafine-induced subacute cutaneous lupus erythematosus	3
Safety evaluation of the trastuzumab biosimilar in Iranian women with HER2-positive breast cancer undergoing adjuvant chemotherapy: a post-marketing surveillance	3
Safety assessment of ezetimibe: real-world adverse event analysis from the FAERS database	3
Drug-Induced Thrombocytopenia Severity and Toxicity (DITPst): binary classification of drugs by human thrombocytopenia toxicity	3
Correction	3
Hepatic adverse events with CDK4/6 inhibitors: a systematic review combining meta-analysis and FAERS database	3
Efficacy and safety evaluation of safinamide as an add-on treatment to levodopa for parkinson’s disease	3
Hepatitis B virus reactivation associated with Janus kinase (JAK) inhibitors: a retrospective study of pharmacovigilance databases and review of the literature	3
Evaluation of adverse events of bamlanivimab, bamlanivimab/etesevimab used for COVID-19 based on FAERS database	3
Antiseizure medications as migraine preventatives: a call for action for a teratogenic and neurodevelopmental risk removal	3
Managing the ADR of Stevens-Johnson syndrome/toxic epidermal necrolysis	3